Cabozantinib, targeting VEGFR1-3, receptor tyrosine kinase (KIT), tropomyosin receptor kinase B (TRKB), anexelekto receptor tyrosine kinase (AXL), Rearranged during transfection (RET), tyrosine kinase MET, Fms-like tyrosine kinase-3 (FLT-3), TEK receptor tyrosine kinase (TIE2), for hepatocellular and renal cell carcinomas, and Medullary thyroid cancer. The gene discussed is FLT3; the disease is hereditary clear cell renal cell carcinoma.